Viatris Achieves Four Major Regulatory Milestones Across Diverse Pipeline Including Gene Therapy and Generic Approvals
Key Insights
Viatris received FDA approval for its generic octreotide acetate injectable suspension, marking the company's fourth injectable approval in 2025 and first using microsphere technology.
The FDA accepted the company's New Drug Application for a low-dose estrogen weekly contraceptive patch with a PDUFA date of July 30, 2026, targeting women seeking lower hormone alternatives.
Viatris gained FDA clearance for MR-146, a first-of-its-kind gene therapy using AAV delivery to treat neurotrophic keratopathy (search), with Phase 1/2 trials planned for 2026.
Viatris Inc. announced four significant regulatory achievements spanning its global pipeline, demonstrating the company's expanding capabilities across generic drugs, innovative therapies, and gene therapy platforms. The milestones include an FDA approval, two FDA acceptances for clinical development, and a Japanese regulatory submission.
Generic Octreotide Approval Expands Injectable Portfolio
The FDA approved Viatris's octreotide acetate for injectable suspension, a generic version of Sandostatin LAR Depot. The therapy treats patients with acromegaly (search), severe diarrhea and flushing episodes associated with metastatic carcinoid tumors (search), and profuse watery diarrhea associated with vasoactive intestinal peptide secreting tumors.
This approval represents Viatris's first injectable using microsphere technology and marks the company's fourth injectable FDA approval in 2025, joining iron sucrose, paclitaxel, and liposomal amphotericin B. The achievement underscores Viatris's strategy to expand its generics portfolio with technically complex, high-value products.
Low-Dose Contraceptive Patch Advances to Review
The FDA accepted Viatris's New Drug Application for an investigational low-dose estrogen weekly patch containing 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol for contraception. The application was accepted under the 505(b)(2) regulatory pathway with a target action date of July 30, 2026.
The once-weekly transdermal patch is designed for women of childbearing potential with a BMI below 30 kg/m² who are appropriate candidates for combined hormonal contraception and prefer a non-invasive, reversible option with lower estrogen dosing. The patch delivers approximately 150 mcg of norelgestromin and 17.5 mcg of ethinyl estradiol per day and is applied once weekly for three weeks, followed by a one-week patch-free period.
The NDA is supported by results from the Phase 3 Luminous Study, which demonstrated favorable efficacy and safety profiles along with strong patch adhesion performance. This investigational treatment builds upon Viatris's established transdermal drug delivery capabilities and represents a lifecycle advancement of the contraceptive patch Xulane.
Gene Therapy Platform Enters Clinical Development
The FDA cleared Viatris's Investigational New Drug application for MR-146, an Enriched Tear Film AAV gene therapy candidate for neurotrophic keratopathy (search). The company plans to initiate the Phase 1/2 CORVITA clinical trial for MR-146 in patients with neurotrophic keratopathy in the first half of 2026.
Neurotrophic keratopathy (search) is a rare but potentially sight-threatening corneal disease affecting approximately 73,000 people in the United States. The degenerative disease causes progressive corneal damage, with common causes including viral infections (herpes simplex, varicella zoster), diabetes, multiple sclerosis, chemical burns, dry eye disease, and corneal surgeries.
MR-146 utilizes a first-of-its-kind approach designed for direct delivery to the lacrimal gland via single injection, using non-replicating DNA delivery transporters for production and delivery of human Nerve Growth Factor protein to the cornea via tears. Neurotrophic keratopathy (search) represents the first indication of many that could potentially be treated with this platform.
Japanese Sleep Apnea Application Supported by Phase 3 Data
Japan's Pharmaceuticals and Medical Devices Agency accepted Viatris's Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome (search). The company remains on track to submit a J-NDA for narcolepsy (search) by the end of the year.
Pitolisant is a selective histamine H3 receptor (search) antagonist/inverse agonist that modulates the brain's sleep-wake pathways. The J-NDA application is supported by positive Phase 3 data in Japanese patients with obstructive sleep apnea syndrome (search) experiencing residual excessive daytime sleepiness despite CPAP therapy treatment.
The 12-week Phase 3 trial demonstrated that patients receiving pitolisant scored lower on the Epworth Sleepiness Scale compared to placebo, with a statistically significant difference (p=0.007). Safety and tolerability results were consistent with global clinical studies.
Strategic Pipeline Advancement
"We are proud of these recent regulatory achievements, which culminate a year of significant R&D advancement in 2025," said Philippe Martin, Viatris Chief R&D Officer. "These important milestones not only demonstrate the strength of our scientific and regulatory capabilities, but also our dedication to addressing areas of significant unmet medical need for patients."
The regulatory milestones span all stages of Viatris's global pipeline, from generic approvals to innovative gene therapy platforms, reflecting the company's diversified approach to addressing unmet medical needs across multiple therapeutic areas.